Business
Collaboration Agreement
Collaboration Agreement.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n RNS Number : 6128I Sareum Holdings PLC 16 March 2010 \n\n16 March 2010\nSareum Holdings Plc\n(\"Sareum\" or the \"Company\")\n \nSareum to collaborate with Physiomics, the ICR and CRT on cancer drug development programme\n \nSareum (AIM:SAR), the specialist cancer drug discovery company, and Physiomics plc (AIM: PYC, \"Physiomics\"), the Oxford, UK based systems biology company, are pleased to announce that they have signed an agreement in which Physiomics provides in silico simulations to support Sareum's cancer drug joint research program with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT).\n \nPhysiomics will use its modelling expertise in biological processes to simulate the effects of cancer drugs in living systems. The research programme will focus on finalising dose schedules for a research program compound in combination with a marketed chemotherapeutic. This work will take approximately three months to complete, and will be funded from the proceeds of a commercial deal for the molecule.\n \nDr Tim Mitchell, CEO of Sareum, said: \"We are very pleased to be working with Physiomics and expect their expertise will provide us with a superior drug dose schedule and add extra value to the programme licensing package.\"\n \nDr Christophe Chassagnole, COO of Physiomics, said:\n'We are extremely pleased to start a research collaboration with such renowned partners in the field of cancer research. Our growing list of partners is a testimony to the potential of our technology to answer a key question in cancer drug development: How to find the optimal drug schedule and combination.'\n \nProfessor Paul Workman, Director of the Cancer Research UK Centre for Cancer Therapeutics at the ICR, said:\n \n\"We are delighted to be working with Physiomics to combine their technology with our drug discovery expertise. This collaboration supports the ICR's overall strategy of working in partnership with other leading organisations to accelerate the delivery of new and more effective drugs to cancer patients.\"\n \nEnquiries:\n \n\n\n\n\nSareum Holdings plc\n\n\n\n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\n\n\n\n\n\n\n\n\nMerchant John East Securities Limited (Nominated Adviser)\n\n\n\n\nSimon Clements/Bidhi Bhoma\n\n\n020 7628 2200\n\n\n\n\n\n\n\n\n...